Pharmacist Inhaler Review Cuts Readmissions in COPD, Not Overall
PILLAR shows a predischarge pharmacist inhaler optimization program failed in an unselected long-acting inhaler population but reduced readmissions and emergency visits in the COPD subgroup, informing where respiratory pharmacists should concentrate discharge resources.
📅 Journal publication: Jun 2026(online Feb 12, 2026)·Last updated: Aug 4, 2026
Chronic obstructive pulmonary disease (COPD) significantly contributes to hospital readmissions, which are costly and often preventable. The pharmacist-led intervention reduced the risk of 30-day and 6-month readmissions or emergency department visits for COPD patients, with a hazard ratio of 0.63 and 0.42, respectively. While overall results weren't significant, the intervention notably benefited COPD patients, highlighting the pharmacist's role in optimizing inhaler therapy. Pharmacist interventions can reduce COPD-related readmissions by optimizing inhaler therapy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Parrott TD, Wallace MD, Eble SH, Niehoff KM, Gao Y, Choi L, Prigmore HL, Dear ML, Rice TW, Sevin CM, Choma NN, Zuckerman AD
Citation:Parrott TD, Wallace MD, Eble SH, et al. A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmission (PILLAR): A Randomized Controlled Trial. CHEST pulmonary. 2026;4(2):100231. doi:10.1016/j.chpulm.2025.100231